OR WAIT null SECS
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
Catalent has completed the expansion of its clinical supply facility located in Shanghai, China.
Catalent announced on Dec. 1, 2022 that it has completed the expansion of its clinical supply facility in the Waigaoqiao Free Trade Zone (FTZ) in Shanghai, China.
The expansion increased the facility by approximately 30,000 ft2, which has allowed for the installation of additional refrigerated and deep-frozen storage, as well as expansion of secondary packaging capabilities. The completion of the facility will be marked by two events on Dec. 1 and Dec. 6, 2022, where the facilities at the site will be showcased and workshops on clinical supply management and new GMP policies will be held.
The Waigaoqiao facility is one of two clinical supply facilities that Catalent operates in Shanghai; the other is located in Tangzhen, outside of the FTZ. The two facilities provide sponsors with optimized supply solutions for studies being undertaken in China, the Asia-Pacific region, and globally. These include clinical supply management, comparator sourcing, FastChain demand-led supply, primary and secondary packaging, storage, and global distribution, as well as clinical returns and destruction.
“China is the fastest growing clinical trials market in the Asia-Pacific region, and Catalent continues to invest and expand its facilities and services to offer reliable, flexible, and integrated support to customers,” said Tracey Clare, general manager, APAC Operations, Catalent, in a company press release. “These additional capabilities increase the site’s ability to support clinical trials for advanced therapeutics, which often require specialized storage and handling capabilities.”